Deep Vein Thrombosis Research Today is a free monthly online journal that collates and summarizes the latest research about Deep Vein Thrombosis, including details on dvt, prevention, effects, causes, air travel, blood clots.

Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion.

Wroblewski JJ, Wells JA, Gonzales CR

Cumberland Valley Retina Consultants, Hagerstown, Maryland 21740, USA. JohnW@retinacare.net

PURPOSE: To assess the efficacy and safety of intravitreous pegaptanib sodium (Macugen; EyeTech Pharmaceuticals/Pfizer Inc, New York, New York, USA) for macular edema secondary to branch retinal vein occlusion (BRVO). DESIGN: Prospective, randomized, dose-finding study. METHODS: Twenty subjects from three clinical practices in the United States with BRVO of more than 1 month's and fewer than 6 months' duration; best-corrected visual acuity (BCVA) 70 to 25 Early Treatment Diabetic Retinopathy Study letters inclusive (approximately 20/40 to 20/320 Snellen); and central foveal thickness of 250 microm or more were included. Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3 or 1 mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48. Principal efficacy outcomes were change from baseline to week 54 in BCVA, center point thickness, central subfield thickness, and macular volume as measured by optical coherence tomography. RESULTS: Fifteen subjects received pegaptanib 0.3 mg and 5 received pegaptanib 1 mg. Eighteen subjects completed the 54-week follow-up. Results were similar in both the 0.3- and 1-mg groups. Overall improvements from baseline to week 54 occurred in mean BCVA (+14 +/- 13 letters), center point thickness (-205 +/- 195 mum), central subfield thickness (-201 +/- 153 mum), and macular volume (-2.2 +/- 1.6 mm(3)). The response was rapid after the first injection, with a mean BCVA improvement of 11 +/- 7 letters at 1 week from the baseline of 56 +/- 12 letters (approximately 20/80 Snellen). One retinal detachment and no cases of endophthalmitis or traumatic cataract were seen. CONCLUSIONS: Intravitreous pegaptanib offers a promising alternative as a treatment for macular edema secondary to BRVO.

Published 27 January 2010 in Am J Ophthalmol, 149(1): 147-54.
Full-text of this article is available online (may require subscription).

Articles on Deep Vein Thrombosis published 27 January 2010:

Serous retinal detachment associated with retinal vein occlusion.   Am J Ophthalmol, 149(2): 291-301.e5.

PURPOSE: To study the pathomorphology of serous retinal detachment (RD) associated with retinal vein occlusion by optical coherence tomography (OCT). DESIGN: Retrospective chart review. METHODS: Ninety-one eyes of 91 patients with macular edema associated with retinal vein occlusion had undergone a comprehensive ophthalmologic examination, including measurement by spectral-domain OCT. RESULTS: Eyes with macular edema associated with retinal vein occlusion typically showed foveal cystoid spaces ... [Abstract] [Full-text]

Articles on Deep Vein Thrombosis published 15 January 2010:

Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome.   Blood, 115(2): 388-95.

In Budd-Chiari syndrome (BCS), thrombosis develops in the hepatic veins or inferior vena cava. To study the relationship between hypofibrinolysis and BCS, we measured plasma levels of fibrinolysis proteins in 101 BCS patients and 101 healthy controls and performed a plasma-based clot lysis assay. In BCS patients, plasminogen activator inhibitor 1 (PAI-1) levels were significantly higher than in controls (median, 6.3 vs 1.4 IU/mL, P < .001). Thrombin-activatable fibrinolysis inhibitor and ... [Abstract] [Full-text]

Articles on Deep Vein Thrombosis published 29 December 2009:

Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism.   Ann Surg, 251(1): 76-83.

OBJECTIVE: The aim of this study was to determine the role of antithrombin III (AT-III) in portal vein thrombosis (PVT) after splenectomy in cirrhotic patients. SUMMARY BACKGROUND DATA: There is no standard treatment for PVT after splenectomy in liver cirrhosis. METHODS: A total of 50 consecutive cirrhotic patients who underwent laparoscopic splenectomy for hypersplenism were enrolled into this study. From January 2005 to December 2005, 25 cirrhotic patients received no prophylactic ... [Abstract] [Full-text]

Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study.   Hepatology, 51(1): 210-8.

Current recommendations for early anticoagulation in acute portal vein thrombosis unrelated to cirrhosis or malignancy are based on limited evidence. The aim of this study was to prospectively assess the risk factors, outcome, and prognosis in patients managed according to these recommendations. We enrolled 102 patients with acute thrombosis of the portal vein, or its left or right branch. Laboratory investigations for prothrombotic factors were centralized. Thrombus extension and ... [Abstract] [Full-text]

Articles on Deep Vein Thrombosis published 25 December 2009:

Do not forget the distal lower limb veins in screening patients with spinal cord injuries for deep venous thromboses.   Angiology, 61(1): 78-81.

In this prospective study, we aimed to document the rate and localization of deep venous thromboses in patients with spinal cord injuries. Patients with paraplegia or tetraplegia were screened by a serial color duplex sonography protocol for deep venous thrombosis within the first 36 hours after admission, at day 7, and at day 21. Sonography was performed by a complete scan including the veins below the knee. A total of 139 patients were included (19-90 years, 63.5% male). Cumulative rate of ... [Abstract] [Full-text]

Articles on Deep Vein Thrombosis published 24 December 2009:

Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging.   Radiology, 254(1): 154-62.

PURPOSE: To investigate the utility of diffusion-weighted (DW) imaging in distinguishing bland thrombus from neoplastic thrombus in the portal vein in patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: In this retrospective institutional review board-approved HIPAA-complaint study, the imaging results in 25 patients (16 men [average age, 62.3 years; range, 35-75 years] and nine women [average age, 58.4 years; range, 32-69 years]; overall average age, 60.1 years; range, 32-75 ... [Abstract] [Full-text]

Articles on Deep Vein Thrombosis published 18 December 2009:

Incidence of postthrombotic syndrome in patients undergoing primary total knee arthroplasty for osteoarthritis.   Clin Orthop Relat Res, 468(1): 178-81.

Postthrombotic syndrome (PTS) is characterized by edema, venous ectasia, hyperpigmentation, varicose veins, venous ulceration, and pain with calf compression after deep venous thrombosis (DVT). We determined the incidence of PTS after DVT diagnosed on screening ultrasound in patients undergoing primary total knee arthroplasty (TKA) for osteoarthritis (OA). We retrospectively reviewed the records of 1406 patients who underwent primary TKA for osteoarthritis and compared the incidence of PTS in ... [Abstract] [Full-text]

Articles on Deep Vein Thrombosis published 8 December 2009:

Complications of recombinant activated human coagulation factor VII.   Am J Surg, 198(6): 895-9.

BACKGROUND: Recombinant factor VIIa (rFVIIa) frequently is used for treatment of life-threatening hemorrhage in trauma. METHODS: A retrospective review of injured patients receiving rFVIIa at an American College of Surgeons-verified Level 1 trauma center was performed. Controls were matched for age, sex, Injury Severity Score, and traumatic brain injury. Thrombotic complications in patients administered rFVIIa, including deep venous thrombosis (DVT), pulmonary embolus, acute myocardial ... [Abstract] [Full-text]

© 2004-2010 Deep Vein Thrombosis Research Today. All Rights Reserved.